These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 37326480)
21. Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer. Debie Y; Van Audenaerde JRM; Vandamme T; Croes L; Teuwen LA; Verbruggen L; Vanhoutte G; Marcq E; Verheggen L; Le Blon D; Peeters B; Goossens ME; Pannus P; Ariën KK; Anguille S; Janssens A; Prenen H; Smits ELJ; Vulsteke C; Lion E; Peeters M; van Dam PA Clin Cancer Res; 2023 Feb; 29(3):635-646. PubMed ID: 36341493 [TBL] [Abstract][Full Text] [Related]
22. The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273. Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP Clin Microbiol Infect; 2022 May; 28(5):701-709. PubMed ID: 34547457 [TBL] [Abstract][Full Text] [Related]
23. Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up. Lasagna A; Cassaniti I; Arena F; Bergami F; Percivalle E; Comolli G; Sarasini A; Ferrari A; Cicognini D; Schiavo R; Lo Cascio G; Pedrazzoli P; Baldanti F Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047704 [TBL] [Abstract][Full Text] [Related]
24. Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis. Nemeth D; Vago H; Tothfalusi L; Ulakcsai Z; Becker D; Szabo Z; Rojkovich B; Merkely B; Nagy G Front Immunol; 2022; 13():960001. PubMed ID: 36311767 [TBL] [Abstract][Full Text] [Related]
25. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8 van den Dijssel J; Duurland MC; Konijn VA; Kummer LY; Hagen RR; Kuijper LH; Wieske L; van Dam KP; Stalman EW; Steenhuis M; Geerdes DM; Mok JY; Kragten AH; Menage C; Koets L; Veldhuisen B; Verstegen NJ; van der Schoot CE; van Esch WJ; D'Haens GR; Löwenberg M; Volkers AG; Rispens T; Kuijpers TW; Eftimov F; van Gisbergen KP; van Ham SM; Ten Brinke A; van de Sandt CE; J Autoimmun; 2024 Apr; 144():103175. PubMed ID: 38387105 [TBL] [Abstract][Full Text] [Related]
26. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort. Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871 [TBL] [Abstract][Full Text] [Related]
27. Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern. Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Serra F; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I ESMO Open; 2022 Oct; 7(5):100574. PubMed ID: 36029652 [TBL] [Abstract][Full Text] [Related]
28. Waning humoral immunity of SARS-CoV-2 vaccination in a rheumatoid arthritis cohort and the benefits of a vaccine booster dose. Le Moine C; Soyfoo MS; Mekkaoui L; Dahma H; Tant L Clin Exp Rheumatol; 2023 Jan; 41(1):82-87. PubMed ID: 35699073 [TBL] [Abstract][Full Text] [Related]
29. Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses. Ahmed-Belkacem A; Redjoul R; Brillet R; Ahnou N; Leclerc M; López-Molina DS; Soulier A; Gourgeon A; Rodriguez C; Maury S; Pawlotsky JM; Fourati S Viruses; 2022 Aug; 14(9):. PubMed ID: 36146735 [TBL] [Abstract][Full Text] [Related]
30. Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals. Goh YS; Rouers A; Fong SW; Zhuo NZ; Hor PX; Loh CY; Huang Y; Neo VK; Kam IKJ; Wang B; Ngoh EZX; Salleh SNM; Lee RTC; Pada S; Sun LJ; Ong DLS; Somani J; Lee ES; ; ; Maurer-Stroh S; Wang CI; Leo YS; Ren EC; Lye DC; Young BE; Ng LFP; Renia L Front Immunol; 2022; 13():1031852. PubMed ID: 36451833 [TBL] [Abstract][Full Text] [Related]
31. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses. Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E Front Immunol; 2022; 13():981350. PubMed ID: 36059485 [TBL] [Abstract][Full Text] [Related]
32. Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease. Haberman RH; Herati RS; Simon D; Samanovic M; Blank RB; Tuen M; Koralov SB; Atreya R; Tascilar K; Allen JR; Castillo R; Cornelius AR; Rackoff P; Solomon G; Adhikari S; Azar N; Rosenthal P; Izmirly P; Samuels J; Golden B; Reddy S; Neurath M; Abramson SB; Schett G; Mulligan MJ; Scher JU medRxiv; 2021 May; ():. PubMed ID: 34013285 [TBL] [Abstract][Full Text] [Related]
33. The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study. Al-Janabi A; Ra A; Littlewood Z; Foulkes AC; Hunter HJA; Chinoy H; Moriarty CA; Hyrich KL; Limdi JK; Yiu ZZN; Griffiths CEM; Warren RB Br J Dermatol; 2023 Mar; 188(4):542-551. PubMed ID: 36695406 [TBL] [Abstract][Full Text] [Related]
35. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals. Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S Front Immunol; 2022; 13():876533. PubMed ID: 35711413 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of the T cell and B cell response following the administration of COVID-19 vaccines in Korea. Widyasari K; Jang J; Lee S; Kang T; Kim S J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 1):1013-1024. PubMed ID: 36261313 [TBL] [Abstract][Full Text] [Related]
37. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. Jena A; Mishra S; Deepak P; Kumar-M P; Sharma A; Patel YI; Kennedy NA; Kim AHJ; Sharma V; Sebastian S Autoimmun Rev; 2022 Jan; 21(1):102927. PubMed ID: 34474172 [TBL] [Abstract][Full Text] [Related]
38. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD; Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524 [TBL] [Abstract][Full Text] [Related]
39. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506 [TBL] [Abstract][Full Text] [Related]
40. Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy. Caldera F; Rolak S; Farraye FA; Necela BM; Cogen D; Zona EE; Schell TL; Ramirez OR; Almasry M; Chun K; Hayney MS; Knutson KL Clin Transl Gastroenterol; 2024 Apr; 15(4):e00688. PubMed ID: 38349178 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]